The content creation was supported by Edwards Lifesciences.
At TCT 2025, the PARTNER trials’ long-term data were presented, highlighting the SAPIEN 3 platform durability and performance. The 7-year and 10-year outcomes are setting the standard for TAVI durability and valve performance.
Watch the data presentations from TCT
PARTNER 3 Low‑Risk Trial: 7‑Year Outcomes
PARTNER 2 S3i Intermediate‑Risk Trial: 10‑Year Outcomes
Important considerations when interpreting long-term data
For more information, please contact your local country Edwards representative
Speakers
Michael J. Mack1
Raj Makkar2
Sreekanth Vemulapalli3
- Baylor Scott & White Heart Hospital, Plano, Texas, USA
- Cedars-Sinai Heart Institute, Los Angeles, California, US
- Duke University Medical Center, Durham, North Carolina, US
